

CONTENTS

	Page No.
List of Tables	i - iii
List of Figures and Photos	iv-vi
 Chapter 1: Introduction	 1
 Chapter 2: Literature Review	
2.1 Systemic and Mucosal Immunity	12
2.1.1. Immunity	12
2.1.2. Antigen	13
2.1.3. Vaccine	14
2.1.4. Antibodies	14
2.1.4.1 Structure and function of antibodies	15
2.1.5 Immunization	18
2.1.6 Impact of Current Vaccines	18
2.1.7 Limitations of the current Modes of Vaccination	19
2.1.7.1 Lack of compliance with the multi injection immunization schedule	19
2.1.7.2 Complicated Diseases Require Peripheral and Mucosal Protective Immunity	20
2.1.7.3 Side effects	21
2.1.7.4 Cross Regulation	22
2.1.7.5 Process, Storage and administration to patients	22
2.1.8 Mucosal Immunity	23
2.1.9 Common Mucosal Immune System	24
2.1.10 Development of Oral Vaccine	26
2.1.10.1 Compartmentalization of Immune Responses	26
2.1.10.2 Peripheral Immunity and IgG	30
2.1.10.3 Mucosal Immunity and Secretory IgA	30
2.1.11. Compartmentalized Immunity and Lymphocyte Traffic	31
2.1.12. Oral Tolerance and Mucosal Immunity	33
2.1.12.1 Abrogation of Oral tolerance	34
2.1.12.2 Microencapsulated Vaccines to overcome Oral Tolerance & Cross Regulation	35
2.1.13 References	36
	42
2.2 Tetanus	
2.2.1 History of disease and vaccine	42

2.2.2 Clinical Description	43
2.2.3 Bacteriology	47
2.2.3.1 Pathogenesis	47
2.2.3.2 Mode of action	49
2.2.3.3 Treatment	52
2.2.4 Epidemiology	53
2.2.4.1 Incidence and Descriptive Epidemiology of Non-neonatal Tetanus	53
2.2.4.2 Incidence and Descriptive Epidemiology of Neonatal Tetanus	54
2.2.5 Passive Immunization and Correlation of Serum Antitoxin with Protection	58
2.2.6 Active Immunization Toxoid	58
2.2.6.1 Tetanus Toxoid Production and quality control of tetanus toxoid	58
2.2.6.2 Dosage and Route	60
2.2.6.3 Available Preparations	61
2.2.6.3.1 Constituents	61
2.2.6.3.2 Stability	61
2.2.6.4 Results of Active Immunization	61
2.2.6.5 Indications for Use	62
2.2.6.6 Administration to Infants and Children	62
2.2.6.7 Administration to Adults	63
2.2.6.8 Administration to Women of Child-Bearing Age for Prevention of Neonatal	64
2.2.6.9 Duration of Immunity and Booster Immunization	64
2.2.6.10 Booster Immunization for Prevention of Maternal and Neonatal Tetanus	64
2.2.6.11 Immunization in Immunodeficiency	64
2.2.6.12 Adverse Events Following Immunization	65
2.2.6.13 Simultaneous Administration with Other Vaccines	66
2.2.7 Future Prospects	66
2.2.7.1 Oral vaccines	66
2.2.7.2 Subunit vaccines	66
2.2.7.3 Recombinant DNA vaccine against tetanus	67
2.2.7.4 Tetanus vaccine as carrier of other vaccines	67
2.2.8 References	68

	75
2.3 Diphtheria	
2.3.1 History of the disease and vaccine	75
2.3.2 Clinical Description	76
2.3.2.1 Complications	77
2.3.3 Biology of the Organism and Pathogenesis of Infection	77
2.3.4 Diphtheria Toxin	79
2.3.5 Protective Levels of Antitoxin	82
2.3.6 Epidemiology	82
2.3.7 Treatment of Diphtheria	84
2.3.7.1 Active Immunization	84
2.3.7.2 Passive Immunization	85
2.3.7.3 Postexposure Use of Antitoxin and Toxoid	85
2.3.8 Current Production	85
2.3.9 Available preparations and Immunization schedule	87
2.3.10 Results of Immunization	88
2.3.11 Duration of Immunity	91
2.3.12 Safety of Diphtheria Toxoid	91
2.3.13 Precautions and Contraindications	92
2.3.14 Future Prospects	92
2.3.14.1 CRM 197 as a new vaccine against diphtheria.-	92
2.3.14.1.2 CRM as carrier for polysaccharide vaccines-	93
2.3.14.2 Recombinant vaccines	93
2.3.14.3 Synthetic antigens	93
2.3.15 References	94
2.4 Chitosan	97
2.4.1 Chemical Properties of Chitosan	98
2.4.2 Properties of Chitosan for Pharmaceutical Uses	101
2.4.2.1 Tablet Excipient	101
2.4.2.1.2 Mucoadhesivity	102
2.4.2.1.3 Absorption Promotion	103
2.4.2.1.4 Interaction with Acidic Drug/ Excipients	104
2.4.2.2 Hydrogels	105
2.4.2.3 Polymer Micelles	107
2.4.2.4. Chitosan Microparticulate Systems	107
2.4.2.4.1 Precipitation	108

2.4.2.4.2 Complex Coacervation	108
2.4.2.4.3 Chemical cross-linking	110
2.4.2.4.4 Solvent Evaporation	111
2.4.3. Chitosan and Routes of Drug Administration	112
2.4.3.1 Ophthalmic Delivery	112
2.4.3.2 Nasal Delivery	113
2.4.3.3 Buccal Delivery	114
2.4.3.4 Oral Delivery	115
2.4.3.5 Colon Delivery	116
2.4.3.6 Vaginal Delivery	116
2.4.3.7 Transdermal Delivery	117
2.4.4. Specific Chitosan Applications	118
2.4.4.1 Radiopharmaceuticals	118
2.4.4.2 Gene Delivery	119
2.4.4.3 Peptide Delivery	120
2.4.6 References	124
	134
Chapter 3: Analytical Methods	
3.1. Materials and Reagents	134
3.1.1 Materials	134
3.1.2 Reagents	134
3.2. Analytical Methods	136
3.2.1 Determination of Protein Content by DC Protein Assay	136
3.2.2 Determination of Limes Flocculation Units (Lf)	137
3.2.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)	138
3.2.4 High Performance Liquid Chromatography (HPLC)	140
3.2.5 Determination of Isoelectric point of TT and DT by Isoelectric Focussing	143
3.2.6 Estimation of TT using ELISA	144
3.2.7 Estimation of DT using ELISA	145
3.2.8 Estimation of TT specific IgG from hyper immunized mice sera using ELISA	145
3.2.9 Estimation of TT specific IgG experimental mice sera using ELISA	146
3.2.10 Estimation of DT specific IgG from hyperimmunized mice sera using ELISA	147
3.2.11 Estimation of DT specific IgG from experimental mice sera using ELISA	147
3.2.12 Estimation of TT specific IgA from Fecal matter extracts, Intestinal Lavage solution and Intestinal washings of	147

mice using ELISA	
3.2.13. Estimation of DT specific IgA from Fecal matter extracts, Intestinal Lavage solution and Intestinal washings of mice using ELISA	148
3.3 References	149
Chapter 4: Preformulation	
4.1. Introduction	151
4.2 Materials and Reagents	151
4.2.1 Materials	151
4.2.2 Reagents	152
4.3 Experimental	152
4.3.1 Optimization of RE run Conditions	153
4.3.2 Determination of linearity for TT in RE	153
4.3.3 Validation of RE	153
4.3.3.1 Accuracy of method	153
4.3.3.2 Precision of the method	154
4.3.3.3 Repeatability of the method	154
4.3.4 Application of RE in compatibility studies with different additives	154
4.3.5 <i>In-silico</i> Studies of Interaction	154
4.3.5.1 <i>In-silico</i> Study of Interaction between CS and TT	154
4.3.5.2 <i>In-silico</i> Study of interaction between CS and DT	155
4.4 Results and Discussion	155
4.4.1 Optimization of run conditions	155
4.4.2 Standard curve for TT by RE	156
4.4.3 Validation	158
4.4.3.1 Accuracy	158
4.4.3.2 Precision	158
4.4.3.3 Repeatability	158
4.4.4 Application of RE in compatibility studies with different additives	159
4.4.5 <i>In-silico</i> Study of interactions between Chitosan and toxoids.	163
4.5. Conclusions	165
4.6 References	166

Chapter 5: Formulation Development	168
5.1 Experimental	168
5.1.1 Materials and Methods	168
5.1.2 Solutions and Reagents	169
5.1.3 Characterization	170
5.1.3.1 Chitosan (CS)	170
5.1.3.1.1 Solution pH	170
5.1.3.1.2 Solution Viscosity	170
5.1.3.1.3 Fourier Transform Infra-Red Spectroscopy (FTIR)	170
5.1.3.2 Sodium Tripolyphosphate (STPP)	170
5.1.3.2.1 Solution pH	170
5.1.3.3 Tetanus Toxoid (TT) and Diphtheria Toxoid (DT)	170
5.1.3.3.1 Determination of Limes Flocculation (Lf) Units	170
5.1.3.3.2 Determination of Protein Content by DC Protein Assay	171
5.1.3.3.3 Determination of Molecular Weight of TT and DT	171
5.1.3.3.3.1 Using Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)	171
5.1.3.3.3.2 Using High Performance Liquid Chromatography (HPLC)	171
5.1.3.3.4 Determination of Isoelectric point	171
5.1.3.3.5 Quantitative estimation of TT and DT using HPLC	171
5.1.3.3.5.1 Quantitative estimation of TT	171
5.1.3.3.5.2 Quantitative estimation of DT	172
5.1.3.3.6 Quantitative estimation of TT and DT using ELISA	172
5.1.3.3.6.1 Quantitative estimation of TT	172
5.1.3.3.6.2 Quantitative estimation of DT	172
5.1.4. Preparation of Plain Chitosan Microparticles	172
5.1.4.1 Optimization of amount of STPP to cross-link CS	172
5.1.4.2 Confirmation of CS-STPP complexation using FTIR	173
5.1.5. Preparation of TT Loaded Microparticles	173
5.1.5.1 Optimization of experimental conditions for entrapment of TT-	173

5.1.5.1.1	Effect of viscosity	174
5.1.5.1.2	Volume of water	174
5.1.5.1.3	Effect of pH	174
5.1.5.1.4	Effect of rate of STPP addition	174
5.1.5.2	Preparation of DT loaded CS microparticles-	174
5.1.6	Optimization of Toxoid loading in CS microparticles	174
5.1.6.1	Tetanus Toxoid Loading	175
5.1.6.2	Diphtheria Toxoid Loading	175
5.1.7	Optimization of the Particle size of Final Optimized Formulation	175
5.1.8	Transmission Electron Microscopy (TEM)	178
5.1.9	Environmental-Scanning Electron Microscopy (E-SEM)	178
5.1.10	Effect of high shear rate on the conformational changes	178
5.1.11	Preparation of TT/DT adsorbed vaccine for parenteral use	178
5.1.12	Release study of TT and DT in 0.1 N HCl and Phosphate Buffered saline (pH 7.4)	179
5.1.13	Bioadhesion Testing	179
5.1.14	Rheological studies	179
5.1.15	Sedimentation study	179
5.1.16	Redispersion Study	179
5.1.17	Stability Studies	180
5.1.18	In-Vivo Studies	180
5.1.18.1	Hyperimmunization of mice	180
5.1.18.2	Estimation of TT and DT specific IgG in hyperimmunized mice using ELISA	180
5.1.18.3	Systemic Immune response study	180
5.1.18.3.1	Dose Response Relationship study	181
5.1.18.3.2	Assessment of Systemic Immune Response	181
5.1.18.3.3	Estimation of TT and DT specific IgG in experimental mice using ELISA	181
5.1.18.4	Assessment of Local Immune Response in BALB/c Mice	182

5.1.18.4.1	Procedure for Collection of intestinal lavage fluid	182
5.1.18.4.2	Procedure for Collection of faecal samples	182
5.1.18.4.3	Procedure for Collection of Intestinal washings	182
5.1.18.4.4	Protocol 3 for assessment of Local Immune Response.	183
5.1.18.5	Estimation TT and DT specific IgA in experimental animals using ELISA	183
		184
5.2	Results and Discussion	
5.2.1	Characterization of Chitosan (CS)	184
5.2.1.1	pH of solution	184
5.2.1.2	Viscosity of solution	184
5.2.1.3	Fourier transform Infra-Red spectroscopy (FTIR)	184
5.2.2.	Solution pH of STPP	184
5.2.3.	Characterization of Tetanus and Diphtheria Toxoid	184
5.2.3.1	Limes flocculation units of TT and DT	184
5.2.3.2	Determination of Protein Content by DC Protein Assay	185
5.2.3.3	Molecular weight determination	187
5.2.3.3.1	Molecular weight determination Using SDS-PAGE	187
5.2.3.3.2	Molecular weight determination using High Performance Liquid Chromatography	188
5.2.3.4	Quantitative estimation of TT and DT	190
5.2.3.4.1	Quantitative estimation of TT and DT using HPLC	190
5.2.3.4.1.1	Quantitative estimation of TT	190
5.2.3.4.1.2	Quantitative estimation of DT	191
5.2.3.4.2	Quantitative estimation of TT and DT using ELISA	192
5.2.3.4.2.1	Quantitative estimation of TT	192
5.2.3.4.2.2	Quantitative estimation of DT	193
5.2.3.5	Isoelectric point (pI) of TT and DT	194

5.2.4. Preparation of microparticles	196
5.2.4.1 Optimization of Amount of STPP to Crosslink CS	196
5.2.4.2 Fourier Transform Infra Red Spectroscopy of CS and CS-STPP complex	197
5.2.5. Preparation of TT loaded microparticles	199
5.2.5.1 ELISA for unentrapped TT	199
5.2.5.2 Optimization of Experimental conditions	199
5.2.5.2.1 Viscosity of the reaction medium	199
5.2.5.2.2 Volume of the water	200
5.2.5.2.3 pH of reaction medium	201
5.2.5.2.4 Rate of STPP addition	201
5.2.6. Preparation of DT loaded microparticles	202
5.2.7. Optimization of Toxoid loading in CS microparticles	203
5.2.7.1 Collaboration of ELISA with HPLC	204
5.2.8. Optimization of the Particle size of Final Optimized Formulation	207
5.2.8.1 Scanning Electron Microscopy (SEM)	212
5.2.8.2 Transmission Electron Microscopy (TEM)	215
5.2.9. Effect of high shear rate on conformational changes	216
5.2.9.1 Study of change in conformations using SDS-PAGE	216
5.2.9.2 Study of change in conformations using HPLC	217
5.2.10. Release study of 27TT and 28DT	219
5.2.11. Bioadhesion testing	220
5.2.12. Rheological Study	221
5.2.13. Sedimentation study	222
5.2.14. Redispersion study	223
5.2.15. Stability Study	223
5.2.16. Hyperimmunization of mice	224
5.2.17. Estimation of TT and DT specific IgG in hyperimmunized mice using ELISA	224
5.2.18. Estimation of TT and DT specific IgG in experimental mice using ELISA	226

5.2.19. Assessment of Systemic Immune Response Study	227
5.2.19.1 Dose Response Relationship	227
5.2.19.2. Assessment of Systemic Kinetic Immune Response	231
5.2.19.2.1 Assessment of Systemic Immune Response for TT	231
5.2.19.2.2 Assessment of Systemic Immune Response for DT	233
5.2.20. Assessment of Local Immune Response	235
5.2.20.1 Local immune response in intestinal lavage	235
5.2.20.1.1 Local immune response in intestinal lavage for TT	235
5.2.20.1.2 Local immune response in intestinal lavage for DT	236
5.2.20.2 Local immune response in Faeces	238
5.2.20.2.1 Local immune response in faeces for TT	238
5.2.20.2.2 Local immune response in faeces for DT	239
5.2.20.3 Local immune response in Intestinal washings	241
5.2.20.3.1 Local immune response in Intestinal washings for TT	241
5.2.20.3.2 Local immune response in Intestinal washings for DT	241
5.3 References	243
Chapter 6: Summary and Conclusions	247
Chapter 7: Presentations and Publication	255